How to buy Regeneron Pharmaceuticals stock in Canada

Regeneron Pharmaceuticals is a biotechnology business based in the US. Regeneron Pharmaceuticals shares (REGN) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $701.85 – a decrease of 4.03% over the previous week. Regeneron Pharmaceuticals employs 14,165 staff and has a trailing 12-month revenue of around $13.8 billion.

Our top picks for where to buy Regeneron Pharmaceuticals stock

Buy Regeneron Pharmaceuticals, Inc. stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Regeneron Pharmaceuticals stock price (NASDAQ: REGN)

Use our graph to track the performance of REGN stocks over time.

Regeneron Pharmaceuticals stocks at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$701.85
52-week range	$712.30 - $1,211.20
50-day moving average more info button	$844.03
200-day moving average more info button	$984.95
Wall St. target price	$1,063.08
PE ratio more info button	17.6667
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$40.45

Is it a good time to buy Regeneron Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Regeneron Pharmaceuticals price performance over time

Historical closes compared with the close of $701.85 from 2024-12-20

1 week (2024-12-13)	-4.03%
1 month (2024-11-22)	-4.90%
3 months (2024-09-20)	-38.70%
6 months (2024-06-21)	-33.36%

1 year (2023-12-22)	-17.11%
2 years (2022-12-22)	-4.33%
3 years (2021-12-22)	13.66%
5 years (2019-12-20)	86.85%

Is Regeneron Pharmaceuticals stock undervalued or overvalued?

Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Regeneron Pharmaceuticals's P/E ratio

Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Regeneron Pharmaceuticals shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stock or simply that they're under-valued.

Regeneron Pharmaceuticals's PEG ratio

Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0634. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Regeneron Pharmaceuticals's EBITDA

Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.6 billion.

The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Regeneron Pharmaceuticals financials

Revenue TTM	$13.8 billion
Operating margin TTM	33.43%
Gross profit TTM	$7 billion
Return on assets TTM	7.41%
Return on equity TTM	17.17%
Profit margin	33.61%
Book value	$272.04
Market Capitalization more info button	$78.5 billion

TTM: trailing 12 months

Regeneron Pharmaceuticals stock dividends

We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.

Regeneron Pharmaceuticals stock price volatility

Over the last 12 months, Regeneron Pharmaceuticals's stocks have ranged in value from as little as $712.3 up to $1211.2. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.142. This would suggest that Regeneron Pharmaceuticals's stocks are less volatile than average (for this exchange).

Regeneron Pharmaceuticals overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Regeneron Pharmaceuticals is owned by insiders or institutions?
Currently 1.571% of Regeneron Pharmaceuticals stocks are held by insiders and 90.685% by institutions. How many people work for Regeneron Pharmaceuticals?
Latest data suggests 14,165 work at Regeneron Pharmaceuticals. When does the fiscal year end for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals's fiscal year ends in December. Where is Regeneron Pharmaceuticals based?
Regeneron Pharmaceuticals's address is: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 What is Regeneron Pharmaceuticals's ISIN number?
Regeneron Pharmaceuticals's international securities identification number is: US75886F1075 What is Regeneron Pharmaceuticals's CUSIP number?
Regeneron Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75886F107

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.